Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Published:2018-09-24 Issue:4 Volume:62 Page:1715-1730
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Tianyu¹,Wu Xiaoxing¹,Guo Changying¹,Zhang Kuojun¹,Xu Jinyi¹^ORCID,Li Zheng²,Jiang Sheng¹^ORCID

Affiliation:

1. State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

2. Department of Nanomedicine, Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States

Funder

Ministry of Science and Technology of the People's Republic of China

Chinese Pharmaceutical Association

National Natural Science Foundation of China

Guangzhou Municipality

Guangdong Province

Yiling Biopharmaceutical Innovation Foundation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00990

Reference127 articles.

1. IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE

2. Cancer immunoediting: from immunosurveillance to tumor escape

3. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

4. Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondria‐Targeted Multifunctional Nanoparticles Combine Cuproptosis and Programmed Cell Death‐1 Downregulation for Cancer Immunotherapy;Advanced Science;2024-07-16

2. Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies;Cancer Letters;2024-07

3. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1;European Journal of Medicinal Chemistry;2024-05

4. Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy;Journal of Medicinal Chemistry;2024-02-13

5. Delivery to, and Reactivation of, the p53 Pathway in Cancer Cells Using a Grafted Cyclotide Conjugated with a Cell-Penetrating Peptide;Journal of Medicinal Chemistry;2024-01-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3